SCHEMBL11973058

SCHEMBL11973058

Cc1cc(NS(=O)(=O)c2ccccc2)c2ncccc2c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 16/20 1.00
▸ TDP1 Q9NUW8 2/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ MMP2 P08253 1/20 0.57
▸ CKS1B P61024 1/20 0.57
▸ SKP2 Q13309 1/20 0.57
▸ G6PD P11413 1/20 0.56
▸ NFKBIA P25963 1/20 0.56
▸ AGTR1 P30556 1/20 0.56
▸ METAP2 P50579 1/20 0.56
▸ METAP1 P53582 1/20 0.56
▸ GLO1 Q04760 1/20 0.56
▸ PAX8 Q06710 1/20 0.56
▸ ATM Q13315 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11997127 0.87 SLC40A1 (0.77) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11973396 0.87 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11972688 0.84 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11973836 0.79 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11973488 0.77 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11973231 0.77 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11973361 0.76 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11973665 0.76 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL11972916 0.76 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AMMP2
SCHEMBL17538438 0.75 CKS1B (0.84) SLC40A1CKS1BSKP2GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
CN-103492028-A Novel sulfonaminoquinoline hepcidin antagonists VIFOR INT AG 2014-01-01 — — CN disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885TDP1 4862/4885MEN1 2680/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885TDP1 4862/4885MEN1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback